| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8827943 | European Urology Focus | 2017 | 10 Pages |
Abstract
With the growing use of immunotherapy in genitourinary malignancies, benefits appear to apply independent of age. As the field advances, detailed reporting on outcomes and toxicities by age will be informative for both patients and physicians when discussing treatment options.
Related Topics
Health Sciences
Medicine and Dentistry
Urology
Authors
Aly-Khan A. Lalani, Dominick Bossé, Bradley A. McGregor, Toni K. Choueiri,